Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study
Background: Introduction of human papillomavirus (HPV) vaccination in settings with the highest burden of HPV is not universal, partly because of the absence of quantitative estimates of country-specific effects on health and economic costs.We aimed to develop and validate a simple generic model of such effects that could be used and understood in